/EW
EW Stock - Edwards Lifesciences Corporation
Healthcare|Medical - DevicesNYSE
$85.66+1.01%
+$0.86 (+1.01%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.72
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).66
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+8.2%upside
Target: $92.68
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EW
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$84.80 – $86.52
TARGET (TP)$92.69
STOP LOSS$78.81
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.97
52W High$87.89
52W Low$65.94
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.44B | $5.01B | $5.38B | $5.23B | $4.39B |
| Gross Profit | $4.32B | $3.97B | $4.22B | $4.01B | $3.29B |
| Gross Margin | 79.5% | 79.3% | 78.3% | 76.6% | 74.9% |
| Operating Income | $1.38B | $1.43B | $1.70B | $1.61B | $1.30B |
| Net Income | $4.17B | $1.40B | $1.52B | $1.50B | $823.40M |
| Net Margin | 76.7% | 28.0% | 28.3% | 28.7% | 18.8% |
| EPS | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 |
Company Overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
17
52%
Hold / Neutral
13
39%
Sell / Underperform
3
9%
Analyst Consensus🟡 Mixed
17 Bullish16 Neutral/Bearish
Price Targets
$89
Average Target
↑ 4.2% Upside
Now
$57
Low
$89
Average
$145
High
Based on 34 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | JP Morgan | Upgrade | Overweight | $100 |
| November 3rd 2025 | Raymond James | Upgrade | Outperform | $96 |
| October 29th 2025 | Wolfe Research | Upgrade | Peer Perform | - |
| October 29th 2025 | Jefferies | Upgrade | Buy | $98 |
| October 8th 2025 | Oppenheimer | Downgrade | Perform | - |
| October 7th 2025 | Evercore ISI | Upgrade | Outperform | $88 |
| July 29th 2025 | BTIG Research | Upgrade | Buy | $100 |
| April 24th 2025 | Piper Sandler | Upgrade | Overweight | $80 |
| January 30th 2025 | Stifel | Upgrade | Buy | $90← $75 |
| January 16th 2025 | Wolfe Research | Downgrade | Underperform | $60 |
| December 16th 2024 | BofA Securities | Upgrade | Buy | - |
| October 11th 2024 | Morgan Stanley | Resumed | Equal Weight | $70 |
| September 18th 2024 | Jefferies | Downgrade | Hold | $70← $85 |
| July 31st 2024 | Daiwa Securities | Upgrade | Outperform | - |
| July 29th 2024 | Wolfe Research | Upgrade | Peer Perform | - |
Earnings History & Surprises
EWBeat Rate
72%
Last 18 quarters
Avg Surprise
+3.3%
EPS vs Estimate
Beats / Misses
13/3
2 met exactly
Latest EPS
$0.67
Q4 2025
EPS Surprise History
Q1 24
0.0%
$0.64vs$0.64
Q2 24
+3.1%
$0.66vs$0.64
Q3 24
+1.4%
$0.70vs$0.69
Q4 24
+0.8%
$0.67vs$0.67
Q1 25
+7.1%
$0.59vs$0.55
Q2 25
+7.4%
$0.64vs$0.60
Q3 25
+7.4%
$0.67vs$0.62
Q4 25
+12.4%
$0.67vs$0.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $0.61 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.60 | $0.67 | +12.4% | ✓ BEAT |
Q3 2025 | Jul 24, 2025 | $0.62 | $0.67 | +7.4% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $0.60 | $0.64 | +7.4% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $0.55 | $0.59 | +7.1% | ✓ BEAT |
Q4 2024 | Oct 24, 2024 | $0.67 | $0.67 | +0.8% | ✓ BEAT |
Q3 2024 | Jul 24, 2024 | $0.69 | $0.70 | +1.4% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $0.64 | $0.66 | +3.1% | ✓ BEAT |
Q1 2024 | Feb 6, 2024 | $0.64 | $0.64 | 0.0% | = MET |
Q4 2023 | Oct 25, 2023 | $0.59 | $0.59 | 0.0% | = MET |
Q3 2023 | Jul 26, 2023 | $0.65 | $0.66 | +1.5% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.61 | $0.62 | +1.6% | ✓ BEAT |
Q1 2023 | Jan 31, 2023 | $0.61 | $0.64 | +4.9% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $0.62 | $0.61 | -1.6% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $0.64 | $0.63 | -1.6% | ✗ MISS |
Q2 2022 | Apr 26, 2022 | $0.57 | $0.60 | +5.3% | ✓ BEAT |
Q1 2022 | Jan 26, 2022 | $0.55 | $0.51 | -7.3% | ✗ MISS |
Q4 2021 | Oct 27, 2021 | $0.53 | $0.54 | +1.9% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.56 | $0.64 | +14.3% | ✓ BEAT |
Latest News
JP Morgan Upgrades Edwards Lifesciences to Overweight, Raises Price Target to $100
📈 PositiveBenzinga•Dec 18, 2025, 01:40 PM
Baird Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $87
➖ NeutralBenzinga•Dec 16, 2025, 11:30 AM
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $101
📈 PositiveBenzinga•Dec 11, 2025, 08:59 PM•Also:
Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $103
📈 PositiveBenzinga•Dec 8, 2025, 03:38 PM•Also:
Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $89
➖ NeutralBenzinga•Dec 5, 2025, 07:12 PM•Also:
Stifel Maintains Buy on Edwards Lifesciences, Raises Price Target to $100
📈 PositiveBenzinga•Dec 5, 2025, 05:38 PM•Also:
UBS Maintains Neutral on Edwards Lifesciences, Raises Price Target to $92
➖ NeutralBenzinga•Dec 5, 2025, 04:26 PM•Also:
Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $96
📈 PositiveBenzinga•Dec 5, 2025, 04:15 PM
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $92
➖ NeutralBenzinga•Dec 5, 2025, 03:52 PM
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100
📈 PositiveBenzinga•Dec 5, 2025, 02:25 PM
Baird Maintains Neutral on Edwards Lifesciences, Raises Price Target to $88
➖ NeutralBenzinga•Dec 5, 2025, 12:48 PM
BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $103
📈 PositiveBenzinga•Dec 5, 2025, 10:43 AM
Edwards Lifesciences Outlines 2026 Growth Strategy, Projects 8%-10% Sales Growth And EPS Of $2.80-$2.95 While Expanding Structural Heart Portfolio; Reaffirms Previously Increased 2025 Total Company Constant Currency Sales Growth Guidance Of The High End Of 9% To 10% And EPS Of $2.56-$2.62
📈 PositiveBenzinga•Dec 4, 2025, 02:09 PM
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $100 Price Target
📈 PositiveBenzinga•Nov 25, 2025, 11:05 AM
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $90
➖ NeutralBenzinga•Nov 3, 2025, 03:22 PM
Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $84
➖ NeutralBenzinga•Nov 3, 2025, 01:28 PM•Also:
Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $99
📈 PositiveBenzinga•Oct 31, 2025, 08:57 PM•Also:
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $96
📈 PositiveBenzinga•Oct 31, 2025, 07:55 PM•Also:
JP Morgan Maintains Neutral on Edwards Lifesciences, Raises Price Target to $90
➖ NeutralBenzinga•Oct 31, 2025, 06:31 PM
Goldman Sachs Maintains Buy on Edwards Lifesciences, Raises Price Target to $104
📈 PositiveBenzinga•Oct 31, 2025, 05:56 PM
Frequently Asked Questions about EW
What is EW's current stock price?
Edwards Lifesciences Corporation (EW) is currently trading at $85.66 per share. The stock has moved +1.01% today.
What is the analyst price target for EW?
The average analyst price target for EW is $92.69, based on 1 analyst.
What sector is Edwards Lifesciences Corporation in?
Edwards Lifesciences Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NYSE exchange.
What is EW's market cap?
Edwards Lifesciences Corporation has a market capitalization of $50.30 billion, making it a large-cap company.
Does EW pay dividends?
No, Edwards Lifesciences Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorA
Agilent Technologies, Inc.
$137.24
Mkt Cap: $38.9B
ALC
Alcon Inc.
$79.97
Mkt Cap: $39.6B
ARGX
argenx SE
$854.99
Mkt Cap: $52.3B
BDX
Becton, Dickinson and Company
$195.59
Mkt Cap: $56.3B
BRKR
Bruker Corporation
$46.48
Mkt Cap: $7.1B
CAH
Cardinal Health, Inc.
$202.95
Mkt Cap: $48.2B
DXCM
DexCom, Inc.
$66.06
Mkt Cap: $25.8B
HLN
Haleon plc
$9.90
Mkt Cap: $44.9B
STE
STERIS plc
$254.34
Mkt Cap: $25.0B
VEEV
Veeva Systems Inc.
$221.86
Mkt Cap: $36.5B
Explore stocks similar to EW for comparison